Nabriva Therapeutics plc - NBRV STOCK NEWS

Nabriva Therapeutics plc (NASDAQ: NBRV) has granted stock options to purchase a total of 2,250 shares as an inducement to a new employee. Effective June 30, 2021, the options have an exercise price of $1.35 per share and a ten-year term, vesting over four years. This grant aligns with Nasdaq's inducement grant exception and aims to enhance compensation for the hire. Nabriva is known for its work in anti-infective agents, including the FDA-approved XENLETA® for community-acquired bacterial pneumonia and the development of CONTEPO™ for complicated urinary tract infections.

Nabriva Therapeutics (NASDAQ: NBRV) announced a delay in principal repayments on its loan agreement with Hercules Capital until at least January 1, 2022. This extension provides Nabriva with improved cash flow and extends its cash runway significantly through Q1 2022. The company has also raised funds through its at-the-market offering facility, enabling it to cover operating expenses, debt obligations, and capital needs. Nabriva aims to boost commercialization efforts for its products, XENLETA and SIVEXTRO, to enhance awareness and drive revenue growth.

Nabriva Therapeutics (NASDAQ: NBRV) announced the appointment of Dr. Mark Corrigan and Lisa Dalton to its Board of Directors, enhancing its leadership team. Dr. Corrigan brings 30 years of pharmaceutical experience, while Ms. Dalton offers over 25 years in human resources and executive management. Concurrently, Dr. George Talbot will not seek re-election after 12 years on the board, though he will continue until the 2021 Annual General Meeting. The company's focus remains on developing innovative anti-infective agents, including XENLETA and CONTEPO.

Nabriva Therapeutics (NASDAQ: NBRV) announced the granting of non-statutory stock options for 6,000 ordinary shares to two new employees, effective May 28, 2021. The exercise price is set at $1.38 per share, aligning with the closing price on the grant date. These stock options have a 10-year term and will vest over four years, contingent on the employees' continued service. This grant was made under Nasdaq's inducement grant exception, highlighting the company's commitment to attracting talent in the biopharmaceutical sector.

Nabriva Therapeutics (NASDAQ: NBRV) announced positive results from Sinovant's Phase 3 study of lefamulin for treating community-acquired bacterial pneumonia in China. The trial showed that 76.8% of patients receiving lefamulin met efficacy endpoints, surpassing the 71.4% of patients treated with moxifloxacin. Lefamulin was reported to be safe and well-tolerated. Sinovant will acquire development rights for lefamulin in Greater China, enhancing its commercialization prospects. An NDA submission to China's NMPA is anticipated soon, with potential market growth in the region.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company focused on anti-infective agents, announced that CEO Ted Schroeder will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, at 2:30 p.m. ET. The presentation can be accessed via the 'Investors' section of Nabriva's website.

Nabriva is known for its FDA-approved XENLETA, the first pleuromutilin antibiotic for community-acquired bacterial pneumonia, and is developing CONTEPO for complicated urinary tract infections. It has an agreement with Merck to market SIVEXTRO.

Nabriva Therapeutics plc (NASDAQ: NBRV) reported Q1 2021 financial results, revealing revenues of $2.5 million, an increase of $1.7 million YoY, attributed to collaboration revenues and SIVEXTRO distributions. The FDA extended the New Drug Application re-submission for CONTEPO to June 19, 2022, citing COVID-19 related travel restrictions. Net operating loss decreased to $14.0 million from $23.3 million in the previous year. Cash and equivalents stood at $54.8 million, expected to cover operating expenses into Q4 2021. The company is focusing on boosting SIVEXTRO and XENLETA prescriber adoption.

Nabriva Therapeutics (NASDAQ: NBRV) announced the grant of non-statutory stock options amounting to 15,000 ordinary shares to two newly-hired employees as part of their employment compensation. The options, effective April 30, 2021, have an exercise price of $1.78 per share, aligning with the closing price on the grant date. Vested over four years, the options require the employees' continued service. Furthermore, the Compensation Committee approved these awards under Nasdaq's inducement grant exception.

Nabriva Therapeutics (NASDAQ: NBRV) will release its first quarter financial results on May 6, 2021, after U.S. markets close. A conference call is scheduled for 4:30 p.m. ET to discuss the results and company highlights. Nabriva, known for its anti-infective agents, received FDA approval for XENLETA, aimed at treating community-acquired bacterial pneumonia. The company also develops CONTEPO for complicated urinary tract infections and has a distribution agreement for SIVEXTRO with Merck & Co.